Skip to content
DataLookout
Menu

NCT06660524

Calcium-Phosphorus Regulation Therapy on Heart Valve Disease

StatusUnknown
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

The change of valve calcification score on CT scan from baseline to 1 year of treatment.
Timeframe: from baseline to 1 year of treatment

Secondary (1)

major cardiovascular events

Arms and interventions

Sevelamer TreatmentExperimental

Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.

Calcium Carbonate TreatmentActive comparator

Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.

Drugs: Sevelamer, Calcium carbonate

Sites

1 site in 1 country

  • Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical ScienceBeijing, Beijing Municipality, China